The following is an excerpt of an op-ed published by Pour Demain in Tech Policy Press . The article provides nuance to the innovation vs...

Current geopolitical tensions and rapid technological developments have necessitated an urgent reassessment of biological risks and their...

Medical diagnostics, biomanufacturing, and many other parts of the bioeconomy rely on synthetic nucleic acids (NAs). Clinicians and...

As the European Union prepares to implement the AI Act, ensuring robust evaluation methods for General Purpose AI (GPAI) models is...

Biotech: Ensure safety to maximise progress. Safeguards needed for responsible innovation.

In an era where General Purpose AI (GPAI) models are becoming increasingly prevalent and powerful, the need for robust incident reporting...

With a return-on-investment of CHF 290 for every CHF 1 spent during an ordinary winter, savings orders of magnitudes higher during a...

In May 2024, the Council of Europe adopted the world's first binding international treaty on artificial intelligence (AI). This landmark...

As the implementation of the EU AI Act begins, a crucial mechanism for enforcing regulations on General Purpose AI (GPAI) models is...

Pour Demain outlines the foundations of a risk management framework upon a request by the OECD.